Satellos Bioscience Inc. MSLE
7.19 USD +0.84 (+13.23%)
At closeNov 6, 2026, 4:00 PM EST
7.19 0.00 0.00%
After hours · Nov 6, 4:00 PM ET
6.42 Day range 7.46
5.59 52-week range 13.01
- YTD
- +22.28%
- 1 year
- +26.14%
- Market cap
- 152.55M
- EPS (ttm)
- -1.95
- YTD return
- +22.28%
- 1-year return
- +26.14%
- Volume
- 290.68K
- Avg volume
- 42.29K
- Open
- 6.57
- Previous close
- 6.35
- Day's range
- 6.42 – 7.46
- 52-week range
- 5.59 – 13.01
5D +0.44 (+6.52%)
Financials — quick view
MSLE Revenue — quarterly 0
MSLE Net income — quarterly -11.72M
MSLE EPS — quarterly -0.56
News
Satellos Bioscience Switches BASECAMP Phase 2 Primary Endpoint To MRI Fat Fraction Following FDA Feedback - Craig-Hallum Initiates Coverage On Satellos Bioscience with Buy Rating, Announces Price Target of $24
Satellos Granted US Patent Covering Lead Drug Candidate Forazapadin And Broader AAK1 Inhibitor Platform 
Satellos Bioscience Completes Enrollment For BASECAMP, Phase 2 Clinical Trial Evaluating Forazapadin For Treatment Of Duchenne Muscular Dystrophy In Ambulatory Boys 7 To 10 Years Of Age 
FDA Clears Satellos Bioscience’s IND Application For Forazapadin For Treatment Of Facioscapulohumeral Muscular Dystrophy - HC Wainwright & Co. Reiterates Buy on Satellos Bioscience, Maintains $18 Price Target
- Satellos Bioscience Q2 EPS $(0.56) Misses $(0.45) Estimate
HC Wainwright & Co. Maintains Buy on Satellos Bioscience, Raises Price Target to $18 
Satellos Bioscience Duchenne Drug Candidate's Interim Data Boosts Confidence 
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Your note
Sign in to keep a note on MSLE — it syncs with the Stock Master app.